Keros Therapeutics (KROS) EBT Margin (2019 - 2025)
Keros Therapeutics filings provide 6 years of EBT Margin readings, the most recent being 4328.42% for Q4 2025.
- On a quarterly basis, EBT Margin fell 1332960.0% to 4328.42% in Q4 2025 year-over-year; TTM through Dec 2025 was 37.62%, a 15583988.0% decrease, with the full-year FY2025 number at 37.65%, changed N/A from a year prior.
- EBT Margin hit 4328.42% in Q4 2025 for Keros Therapeutics, down from 61.03% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 9001.18% in Q4 2024 to a low of 541000.0% in Q3 2023.
- Median EBT Margin over the past 5 years was 181.19% (2025), compared with a mean of 54401.17%.
- Biggest five-year swings in EBT Margin: surged 52735155bps in 2024 and later crashed -1332960bps in 2025.
- Keros Therapeutics' EBT Margin stood at 27.6% in 2021, then tumbled by -387bps to 134.37% in 2022, then crashed by -24077bps to 32486.01% in 2023, then surged by 128bps to 9001.18% in 2024, then tumbled by -148bps to 4328.42% in 2025.
- The last three reported values for EBT Margin were 4328.42% (Q4 2025), 61.03% (Q3 2025), and 181.19% (Q2 2025) per Business Quant data.